These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

740 related articles for article (PubMed ID: 23358650)

  • 1. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.
    Tabernero J; Shapiro GI; LoRusso PM; Cervantes A; Schwartz GK; Weiss GJ; Paz-Ares L; Cho DC; Infante JR; Alsina M; Gounder MM; Falzone R; Harrop J; White AC; Toudjarska I; Bumcrot D; Meyers RE; Hinkle G; Svrzikapa N; Hutabarat RM; Clausen VA; Cehelsky J; Nochur SV; Gamba-Vitalo C; Vaishnaw AK; Sah DW; Gollob JA; Burris HA
    Cancer Discov; 2013 Apr; 3(4):406-17. PubMed ID: 23358650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety profile of RNAi nanomedicines.
    Barros SA; Gollob JA
    Adv Drug Deliv Rev; 2012 Dec; 64(15):1730-7. PubMed ID: 22732527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth.
    Kang MR; Yang G; Place RF; Charisse K; Epstein-Barash H; Manoharan M; Li LC
    Cancer Res; 2012 Oct; 72(19):5069-79. PubMed ID: 22869584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct cytosolic siRNA delivery by reconstituted high density lipoprotein for target-specific therapy of tumor angiogenesis.
    Ding Y; Wang Y; Zhou J; Gu X; Wang W; Liu C; Bao X; Wang C; Li Y; Zhang Q
    Biomaterials; 2014 Aug; 35(25):7214-27. PubMed ID: 24875759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lentivirus-mediated shRNA interference targeting vascular endothelial growth factor inhibits angiogenesis and progression of human pancreatic carcinoma.
    Zhao X; Zhu DM; Gan WJ; Li Z; Zhang JL; Zhao H; Zhou J; Li DC
    Oncol Rep; 2013 Mar; 29(3):1019-26. PubMed ID: 23254994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy.
    Han L; Tang C; Yin C
    Biomaterials; 2014 May; 35(15):4589-600. PubMed ID: 24613049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin.
    Ganesh S; Koser ML; Cyr WA; Chopda GR; Tao J; Shui X; Ying B; Chen D; Pandya P; Chipumuro E; Siddiquee Z; Craig K; Lai C; Dudek H; Monga SP; Wang W; Brown BD; Abrams MT
    Mol Cancer Ther; 2016 Sep; 15(9):2143-54. PubMed ID: 27390343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
    Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
    J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice.
    Judge AD; Robbins M; Tavakoli I; Levi J; Hu L; Fronda A; Ambegia E; McClintock K; MacLachlan I
    J Clin Invest; 2009 Mar; 119(3):661-73. PubMed ID: 19229107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies.
    Weinstein S; Toker IA; Emmanuel R; Ramishetti S; Hazan-Halevy I; Rosenblum D; Goldsmith M; Abraham A; Benjamini O; Bairey O; Raanani P; Nagler A; Lieberman J; Peer D
    Proc Natl Acad Sci U S A; 2016 Jan; 113(1):E16-22. PubMed ID: 26699502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rolling circle transcription-based polymeric siRNA nanoparticles for tumor-targeted delivery.
    Lee JH; Ku SH; Kim MJ; Lee SJ; Kim HC; Kim K; Kim SH; Kwon IC
    J Control Release; 2017 Oct; 263():29-38. PubMed ID: 28373128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinesin spindle protein SiRNA slows tumor progression.
    Marra E; Palombo F; Ciliberto G; Aurisicchio L
    J Cell Physiol; 2013 Jan; 228(1):58-64. PubMed ID: 22552964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.
    Zhao X; Li DC; Zhao H; Li Z; Wang JX; Zhu DM; Zhou J; Cen JN
    Oncol Rep; 2012 Mar; 27(3):628-36. PubMed ID: 22200682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy.
    Santel A; Aleku M; Keil O; Endruschat J; Esche V; Durieux B; Löffler K; Fechtner M; Röhl T; Fisch G; Dames S; Arnold W; Giese K; Klippel A; Kaufmann J
    Gene Ther; 2006 Sep; 13(18):1360-70. PubMed ID: 16625242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA interference targeting hypoxia-inducible factor 1α via a novel multifunctional surfactant attenuates glioma growth in an intracranial mouse model.
    Gillespie DL; Aguirre MT; Ravichandran S; Leishman LL; Berrondo C; Gamboa JT; Wang L; King R; Wang X; Tan M; Malamas A; Lu ZR; Jensen RL
    J Neurosurg; 2015 Feb; 122(2):331-41. PubMed ID: 25423275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts.
    Grzelinski M; Urban-Klein B; Martens T; Lamszus K; Bakowsky U; Höbel S; Czubayko F; Aigner A
    Hum Gene Ther; 2006 Jul; 17(7):751-66. PubMed ID: 16839274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
    DeVincenzo JP
    Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knockdown of β-catenin with dicer-substrate siRNAs reduces liver tumor burden in vivo.
    Dudek H; Wong DH; Arvan R; Shah A; Wortham K; Ying B; Diwanji R; Zhou W; Holmes B; Yang H; Cyr WA; Zhou Y; Shah A; Farkiwala R; Lee M; Li Y; Rettig GR; Collingwood MA; Basu SK; Behlke MA; Brown BD
    Mol Ther; 2014 Jan; 22(1):92-101. PubMed ID: 24089139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current issues of RNAi therapeutics delivery and development.
    Haussecker D
    J Control Release; 2014 Dec; 195():49-54. PubMed ID: 25111131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydrodynamic delivery protocols.
    Rychahou PG; Evers BM
    Methods Mol Biol; 2010; 623():189-95. PubMed ID: 20217552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.